Search Result

Results for "

LPA 5

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) LPL Receptor (9) Phosphodiesterase (PDE) (1) Reference Standards (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Inflammation/Immunology (3) Neurological Disease (5)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107615

*TC LPA5* 4**	LPL Receptor	Cancer
TC LPA5 4 is a LPA₅ (GPR92)-specific non-lipid antagonist. TC LPA5 4 inhibits LPA-induced aggregation of isolated human platelet (LPA₅-RH7777 cell line) with an IC₅₀ of 800 nM. TC LPA5 4 displays selectivity for LPA₅ over 80 other screened agent targets . TC LPA5 4 inhibits cell proliferation and migration of thyroid cancer cells .

HY-114379

AS2717638 2 Publications Verification	LPL Receptor	Neurological Disease Inflammation/Immunology
AS2717638 is a highly selective, brain-penetrant and orally active lysophosphatidic acid receptor 5 (LPA5) antagonist with an IC₅₀ value of 38 nM. AS2717638 is highly selective and shows no significant antagonistic activity against other LPA receptors (LPA1, LPA2, and LPA3). AS2717638 can be used in the research of pain and neuroinflammation-related diseases .

HY-151391

LPA5 antagonist 1	Biochemical Assay Reagents	Neurological Disease
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high blood-brain-barrier permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15706

H2L 5765834 1 Publications Verification	LPL Receptor	Cardiovascular Disease
H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA₁, *LPA₃, and LPA₅, with IC₅₀*s of 94, 752, and 463 nM respectively .

HY-160616

LPA5 antagonist 3	LPL Receptor	Cardiovascular Disease Neurological Disease
LPA5 antagonist 3 (Example 74) is a lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC₅₀ of 170 nM. LPA5 antagonist 3 can be used for the research of pain disorders and atherosclerosis .

HY-151392

LPA5 antagonist 2	LPL Receptor	Neurological Disease Inflammation/Immunology
LPA5 antagonist 2 (compound 65) is a high aqueous solubility *LPA5* (lysophosphatidic acid receptor 5) antagonist. LPA5 antagonist 2 significantly attenuates nociceptive hypersensitivity and it can be used for the research of inflammatory and neuropathic pains .

HY-107615R

*TC LPA5* 4 (Standard)**	Reference Standards LPL Receptor	Cancer
TC LPA5 4 (Standard) is the analytical standard of TC LPA5 4 (HY-107615). This product is intended for research and analytical applications. TC LPA5 4 is a LPA5 (GPR92)-specific non-lipid antagonist. TC LPA5 4 inhibits LPA-induced aggregation of isolated human platelet (LPA5-RH7777 cell line) with an IC₅₀ of 800 nM. TC LPA5 4 displays selectivity for LPA5 over 80 other screened agent targets . TC LPA5 4 inhibits cell proliferation and migration of thyroid cancer cells .

HY-W040176

N-PTyrosine PA ammonium N-Palmitoyl-tyrosine phosphoric acid ammonium	LPL Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
N-PTyrosine PA (N-Palmitoyl-tyrosine phosphoric acid) ammonium is a *lysophosphatidic acid (LPA) receptor* modulator, which exhibits weak inhibitory activity against *LPA1* and partial agonist properties towards *LPA5. N-PTyrosine PA ammonium inhibits the activation of LPA* receptors and downstream responses by competing with agonists for binding sites. N-PTyrosine PA ammonium can induce morphological changes and aggregation, and also inhibit LPA-induced morphological changes through receptor desensitization caused by pre-incubation. N-PTyrosine PA ammonium can be used in the research of related diseases such as atherosclerosis and acute ischemic syndromes (e.g., unstable angina, myocardial infarction, stroke) .

HY-148291

*BrP-LPA* sodium**	LPL Receptor Phosphodiesterase (PDE)	Cancer
BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against *LPA₁* (IC₅₀ = 4520 nM), *LPA₂* (IC₅₀ = 468 nM), *LPA₃, and LPA₄. BrP-LPA* sodium also has partial agonistic activity for *LPA₅, with its EC₅₀* being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer .

HY-W923661

1-Octadecyl lysophosphatidic acid PA(O-18:0/0:0); 1-Oleyl LPA; 1-Octadecyl LPA	LPL Receptor	Others
1-Octadecyl lysophosphatidic acid (compound 10) is a GPR92 receptor (LPA5) activator with potential flavoring effects .

Cat. No.	Product Name		Classification

HY-151391

LPA5 antagonist 1		Alkynes
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high blood-brain-barrier permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.